Nothing Special   »   [go: up one dir, main page]

EA201890648A3 - Диоксолановые аналоги уридина для лечения рака - Google Patents

Диоксолановые аналоги уридина для лечения рака

Info

Publication number
EA201890648A3
EA201890648A3 EA201890648A EA201890648A EA201890648A3 EA 201890648 A3 EA201890648 A3 EA 201890648A3 EA 201890648 A EA201890648 A EA 201890648A EA 201890648 A EA201890648 A EA 201890648A EA 201890648 A3 EA201890648 A3 EA 201890648A3
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer treatment
dioxolane
uridine analogues
analogues
dioxolane uridine
Prior art date
Application number
EA201890648A
Other languages
English (en)
Other versions
EA033300B1 (ru
EA201890648A2 (ru
Inventor
Рикард Бетель
Андеш Энерот
Бьерн Классон
Фредрик Эберг
Original Assignee
Медивир Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Медивир Аб filed Critical Медивир Аб
Publication of EA201890648A2 publication Critical patent/EA201890648A2/ru
Publication of EA201890648A3 publication Critical patent/EA201890648A3/ru
Publication of EA033300B1 publication Critical patent/EA033300B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

В изобретении предложены соединения формулыгде Rпредставляет собой ORили NRR; Rпредставляет собой F; Rпредставляет собой H или C(=O)R; Rпредставляет собой H; Rпредставляет собой C-C-алкил; Rпредставляет собой фенил или нафтил, где фенил возможно замещен 1 R; и другие переменные являются такими, как определено в формуле изобретения, которые являются полезными в лечении рака, а также связанные с ними аспекты.
EA201890648A 2014-08-25 2015-08-24 Диоксолановые аналоги уридина для лечения рака EA033300B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1450983 2014-08-25
SE1550858 2015-06-22

Publications (3)

Publication Number Publication Date
EA201890648A2 EA201890648A2 (ru) 2018-08-31
EA201890648A3 true EA201890648A3 (ru) 2019-02-28
EA033300B1 EA033300B1 (ru) 2019-09-30

Family

ID=54014804

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201790328A EA031106B1 (ru) 2014-08-25 2015-08-24 Диоксолановые аналоги уридина для лечения рака
EA201890648A EA033300B1 (ru) 2014-08-25 2015-08-24 Диоксолановые аналоги уридина для лечения рака

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201790328A EA031106B1 (ru) 2014-08-25 2015-08-24 Диоксолановые аналоги уридина для лечения рака

Country Status (24)

Country Link
US (7) US10144750B2 (ru)
EP (2) EP3572410B1 (ru)
JP (2) JP6663424B2 (ru)
KR (2) KR102396905B1 (ru)
CN (4) CN110804072B (ru)
AU (2) AU2015308988C1 (ru)
BR (1) BR112017003898B1 (ru)
CA (2) CA2956251C (ru)
CY (1) CY1122945T1 (ru)
DK (2) DK3572410T3 (ru)
EA (2) EA031106B1 (ru)
ES (2) ES2927212T3 (ru)
HR (1) HRP20201023T1 (ru)
HU (2) HUE050705T2 (ru)
IL (2) IL250344B (ru)
MX (1) MX369649B (ru)
MY (1) MY188089A (ru)
NZ (2) NZ729118A (ru)
PH (2) PH12017500184A1 (ru)
PL (2) PL3572410T3 (ru)
PT (2) PT3186244T (ru)
SG (3) SG10201911558UA (ru)
WO (1) WO2016030335A1 (ru)
ZA (1) ZA201802864B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6663424B2 (ja) * 2014-08-25 2020-03-11 メディヴィル・アクチエボラーグ 癌の処置のためのウリジンのジオキソラン類似体
CN106543220A (zh) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
JP6889180B2 (ja) 2015-12-11 2021-06-18 ニューカナ パブリック リミテッド カンパニー ホスフェート誘導体及びゲムシタビンプロドラッグｎｕｃ−１０３１のジアステレオ選択性合成
JP6968080B2 (ja) 2016-03-02 2021-11-17 メディヴィル・アクチエボラーグ ソラフェニブ又はレゴラフェニブとトロキサシタビンのホスホロアミデートプロドラッグを用いた併用療法
CN106432328B (zh) * 2016-09-14 2019-03-22 江苏福瑞生物医药有限公司 一种索非布韦中间体的制备方法
MA46839A (fr) * 2016-11-18 2021-03-24 Neurovive Pharmaceutical Ab Promédicaments hépatiques d'ionophores de protons mitochondriaux
GB201709471D0 (en) * 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
JP7337539B2 (ja) * 2018-06-21 2023-09-04 メディヴィル・アクチエボラーグ 白血病療法のための塩基修飾シチジンヌクレオチド
WO2019245444A1 (en) 2018-06-21 2019-12-26 Medivir Ab Base-modified cytidine nucleotides for leukemia therapy
PL3927347T3 (pl) * 2019-02-18 2024-05-06 Medivir Aktiebolag Kombinacja leków do stosowania w sposobie leczenia raka wątroby
CN110964057B (zh) * 2019-12-25 2022-05-06 东南大学 一种利用微流体反应装置制备索非布韦中间体的方法
CN113754692B (zh) * 2020-06-03 2022-06-10 上海交通大学 瑞德西韦中间体(s,s)-氨基磷酸酯的不对称催化合成方法
CN114685558A (zh) * 2020-12-28 2022-07-01 尚科生物医药（上海）有限公司 一种瑞德西韦中间体的制备方法
CN114249764A (zh) * 2021-11-10 2022-03-29 宁波大学 一种磷酰胺酯类前药的中间体及其制备方法与应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
MXPA03003278A (es) * 2000-10-13 2005-07-01 Shire Biochem Inc Analogos de dioxolano para suministro intercelular mejorado.
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
WO2007106450A2 (en) * 2006-03-10 2007-09-20 University Of Georgia Research Foundation, Inc. Diketo acids with nucleobase scaffolds: anti-hiv replication inhibitors targeted at hiv integrase in combination therapy
US20100266674A1 (en) 2006-09-01 2010-10-21 University Of Georgia Research Foundation, Inc. L-oddc prodrugs for cancer
PL216525B1 (pl) 2006-10-17 2014-04-30 Ct Badań Molekularnych I Makromolekularnych Polskiej Akademii Nauk 5'-O-[(N-acylo)amidoditiofosforano] nukleozydy oraz sposób wytwarzania 5'-O-[(N-acylo)amidofosforano]-,5'-O-[(N-acylo)amidotiofosforano]-, 5'-O-[(N-acylo)amidoditiofosforano]nukleozydów
US20130143835A1 (en) * 2011-12-05 2013-06-06 Medivir Ab HCV Polymerase Inhibitors
JP2017504572A (ja) * 2013-11-27 2017-02-09 アイデニクス・ファーマシューティカルズ・エルエルシー 肝臓癌治療のためのヌクレオチド類
JP6663424B2 (ja) * 2014-08-25 2020-03-11 メディヴィル・アクチエボラーグ 癌の処置のためのウリジンのジオキソラン類似体

Also Published As

Publication number Publication date
MX2017002328A (es) 2017-05-22
KR20200035482A (ko) 2020-04-03
CA3128645C (en) 2023-06-27
US20200239502A1 (en) 2020-07-30
HRP20201023T1 (hr) 2020-10-16
CY1122945T1 (el) 2021-10-29
IL266766B (en) 2020-05-31
CN110790789A (zh) 2020-02-14
CN110804072B (zh) 2023-05-12
PT3186244T (pt) 2020-05-29
EP3186244A1 (en) 2017-07-05
EA033300B1 (ru) 2019-09-30
US10336780B2 (en) 2019-07-02
EA201890648A2 (ru) 2018-08-31
US10822360B2 (en) 2020-11-03
US11447511B2 (en) 2022-09-20
US20190389890A1 (en) 2019-12-26
US10654877B2 (en) 2020-05-19
NZ762628A (en) 2023-04-28
ZA201802864B (en) 2019-07-31
AU2018201980B2 (en) 2019-05-16
PL3186244T3 (pl) 2020-11-16
CA2956251A1 (en) 2016-03-03
EA031106B1 (ru) 2018-11-30
CA2956251C (en) 2022-10-25
KR102398714B1 (ko) 2022-05-17
US10144750B2 (en) 2018-12-04
BR112017003898A2 (pt) 2017-12-05
EP3572410B1 (en) 2022-07-20
US20210054008A1 (en) 2021-02-25
AU2018201980A1 (en) 2018-04-12
CA3128645A1 (en) 2016-03-03
US20170267705A1 (en) 2017-09-21
IL266766A (en) 2019-07-31
EP3572410A1 (en) 2019-11-27
HUE050705T2 (hu) 2020-12-28
CN107074826B (zh) 2020-05-22
JP6905609B2 (ja) 2021-07-21
SG11201701172SA (en) 2017-03-30
ES2796089T3 (es) 2020-11-25
PH12017500184B1 (en) 2017-06-28
PH12019501919A1 (en) 2020-09-14
DK3572410T3 (da) 2022-08-29
IL250344A0 (en) 2017-03-30
MX369649B (es) 2019-11-15
WO2016030335A1 (en) 2016-03-03
ES2927212T3 (es) 2022-11-03
AU2015308988C1 (en) 2018-09-06
PT3572410T (pt) 2022-09-15
SG10201911558UA (en) 2020-01-30
BR112017003898B1 (pt) 2022-10-18
US20190100541A1 (en) 2019-04-04
US20230117570A1 (en) 2023-04-20
US20230382931A1 (en) 2023-11-30
KR20170046736A (ko) 2017-05-02
JP6663424B2 (ja) 2020-03-11
PL3572410T3 (pl) 2022-10-03
CN107074826A (zh) 2017-08-18
JP2020090535A (ja) 2020-06-11
CN111269264A (zh) 2020-06-12
AU2015308988A1 (en) 2017-02-23
CN110790789B (zh) 2023-05-12
HUE059640T2 (hu) 2022-12-28
AU2015308988B2 (en) 2018-04-26
PH12017500184A1 (en) 2017-06-28
SG10202001117YA (en) 2020-04-29
EP3186244B1 (en) 2020-04-22
KR102396905B1 (ko) 2022-05-13
IL250344B (en) 2020-01-30
DK3186244T3 (da) 2020-07-13
CN110804072A (zh) 2020-02-18
JP2017526677A (ja) 2017-09-14
EA201790328A1 (ru) 2017-08-31
MY188089A (en) 2021-11-17
NZ729118A (en) 2022-02-25

Similar Documents

Publication Publication Date Title
EA201890648A2 (ru) Диоксолановые аналоги уридина для лечения рака
EA201990221A1 (ru) 1,3-дигидроксифенильные производные, применимые в качестве иммуномодуляторов
EA201991862A1 (ru) Композиции и способы, предназначенные для лечения гемоглобинопатий
EA201892147A1 (ru) Бициклические соединения
EA201990495A1 (ru) Биарильные соединения, применимые в качестве иммуномодуляторов
EA201990912A1 (ru) Анти-lag-3 антитела и их композиции
EA201890857A1 (ru) Соединения, применимые в качестве иммуномодуляторов
EA201691857A1 (ru) Соединения, применимые в качестве иммуномодуляторов
EA201691261A1 (ru) Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
EA201792535A1 (ru) Гетероциклические амиды в качестве ингибиторов киназ
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
EA201691726A1 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
EA201890373A1 (ru) Пиридиновые соединения, пригодные для борьбы с фитопатогенными грибами
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201591382A1 (ru) Ингибиторы гистондеметилаз
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
EA201592126A1 (ru) 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
EA201691913A1 (ru) Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов
EA201890858A1 (ru) 2,4-дигидроксиникотинамиды как агонисты apj
EA201991580A1 (ru) Пиримидиновое соединение и его фармацевтическое применение
EA201990400A1 (ru) Соединения и композиции и их применение
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM